Oseni Approval History

• FDA approved: Yes (First approved January 25th, 2013)
• Brand name: Oseni
• Generic name: alogliptin and pioglitazone
• Previous name: SYR-322/Actos
• Company: Takeda Pharmaceutical Company Limited
• Treatment for: Diabetes, Type 2

Oseni (alogliptin and pioglitazone) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and thiazolidinedione fixed-dose combination for the treatment of type 2 diabetes.

FDA Approval History for Oseni

Date	Article
Jan 25, 2013	Takeda Receives FDA Approval for Oseni (alogliptin and pioglitazone) for Type 2 Diabetes
Sep  4, 2009	Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Jul 23, 2009	Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and Actos (pioglitazone HCl)
Sep 24, 2008	Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / Actos (pioglitazone HCl) for the Treatment of Type 2 Diabetes

See also...

Oseni (alogliptin and pioglitazone) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.